^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AU-101

    i
    Associations
    News

    Trials

    Company:
    Aurora Biopharma, Baylor College of Medicine
    Drug class:
    HER2-targeted CAR-T immunotherapy, CD28-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (NCT00902044)
    Phase 1
    Baylor College of Medicine
    Active, not recruiting
    Last update posted :
    01/12/2024
    Initiation :
    02/11/2010
    Primary completion :
    12/06/2019
    Completion :
    07/01/2032
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    cyclophosphamide • fludarabine IV • AU-101 • cyclophosphamide intravenous
    T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR) (NCT02442297)
    Phase 1
    Baylor College of Medicine
    Active, not recruiting
    Last update posted :
    08/14/2023
    Initiation :
    04/01/2016
    Primary completion :
    04/27/2022
    Completion :
    04/01/2037
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    AU-101